Oncologist and organizational factors associated with variation in breast cancer multigene testing

Abstract

Purpose Multigene testing for breast cancer recurrence risk became available in 2007, yet many eligible patients remain untested. This study evaluated variation in testing rates, and oncologist and organizational factors associated with variation, in a setting without financial influences on testing. Methods We conducted a retrospective cohort study using electronic data and oncologist surveys within Kaiser Permanente Northern California, a large integrated health care system. Analyses included all 2,974 test-eligible patients from 2013–15, 113 oncologists, and 15 practice groups. Receipt of multigene testing was evaluated with generalized linear mixed models. Results Overall, 39% of eligible patients had multigene testing, but rates varied widely among practice groups, ranging from 24 to 48% after case-mix adjustment. This 24% difference among practices was greater than the variation associated with most patient characteristics, including comorbidities and race/ethnicity, and similar to that associated with tumor size. Practice group and oncologist factors were statistically significant contributors to the variation in testing after adjusting for patient factors. Patients were more likely to be tested if they had a female oncologist (aOR 1.60, 95% CI 1.21 – 2.12) or were in a practice whose chief had a high testing rate (aOR 1.20, 95% CI 1.12 – 1.29 per 10% increase in the percent tested). Conclusions Oncologist and leadership practices play a key role in the variation in genomic test use for cancer recurrence risk even in a healthcare system without financial barriers to testing, and could be a leverage point for implementing desired practice changes for new genomic advances.

Uptake of the 21-Gene Assay Among Women With Node-Positive, Hormone Receptor−Positive Breast Cancer

“…In a qualitative study, local practice patterns and peer use of the test were found to influence clinicians' adoption of the assay. 23 Similarly, a recent Kaiser Permanente study found that differences in oncologist factors (eg, sex) and organizational factors (eg, use patterns among practice leaders) explained more variation in testing rates than patientlevel characteristics, 24 and another study (conducted in a single state) found that the likelihood of testing decreased for women when a clinician's patient volume decreased. 25 Thus, clinician-and organizationallevel factors may partially explain geographic variation in test uptake.…”

The impact of gene expression profile testing on confidence in chemotherapy decisions and prognostic expectations

“…The observed rate of test receipt in KPNC is similar to or higher than that in most other settings. [13] Fourth, our results are limited to two large geographic regions in the Western United States. The respondents in this study were more likely to be white and more highly educated than women with breast cancer nationwide.…”

“…The current report uses data from a larger multi-site, collaborative National Cancer Institute-funded study of GEP. [13–15] All participating site Institutional Review Boards approved the study.…”

The leadership behaviors needed to implement clinical genomics at scale: a qualitative study

“…Using the Geisinger Health System and Kaiser Permanente as examples, Reinke 27 identifies the need for leadership to encourage medical practitioners to make the move from genetics to genomics, noting that without this engagement, implementation will not succeed. Furthermore, Lieu et al 28 reported oncologists' genomic practices were influenced by leadership, placing this variable even ahead of funding, and argued for the need to leverage this to facilitate implementation.…”